All Reports
Reports / Rheumatology Reports
Rheumatology Reports
Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed.
Rapid turnaround monitor for highly dynamic healthcare segments
-
Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis US (annual)
- Multi-Specialty Management of Gout US (coming 2019)
-
Psoriatic Arthritis US (quarterly)
-
Psoriatic Arthritis EU (annual)
-
Rheumatoid Arthritis US (quarterly)
-
Rheumatoid Arthritis EU (bi-annual)
- Systemic Lupus Erythematosus US (coming 2019)
Retrospective analysis of 1,000+/- patient charts
-
Biologic/Otezla Switching in Psoriatic Arthritis US
- Biologic/Otezla Switching in Psoriatic Arthritis EU (coming 2019)
-
Biologic/JAK Switching in Rheumatoid Arthritis US
-
Biologic/JAK Switching in Rheumatoid Arthritis EU
-
Systemic Lupus Erythematosus US
Learn more about our work in the rheumatology space.